Ubiquitin-Specific Protease 25 Aggravates Acute Pancreatitis and Acute Pancreatitis-Related Multiple Organ Injury by Destroying Tight Junctions Through Activation of The STAT3 Pathway

Zhengru Liu†, Mingming Qi, Shan Tian, Qian Yang, Jian Liu, Siwei Wang, Mengyao Ji, Rong Yu, Suqi Zeng, Jinting Li, Yuping Wei and Weiguo Dong‡

Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, China

UBIQUITIN-SPECIFIC PROTEASE 25 (USP25) PLAYS AN IMPORTANT ROLE IN INFLAMMATION AND IMMUNITY. HOWEVER, THE ROLE OF USP25 IN ACUTE PANCREATITIS (AP) IS STILL UNCLEAR. TO EVALUATE THE ROLE OF USP25 IN AP, WE CONDUCTED RESEARCH ON CLINICAL AP PATIENTS, USP25 WILD-TYPE (WT)/USP25 KNOCKOUT (USP25−/−) MICE, AND PANCREATIC ACINAR CELLS. OUR RESULTS SHOWED THAT SERUM USP25 CONCENTRATION WAS HIGHER IN AP PATIENTS THAN IN HEALTHY CONTROLS AND WAS POSITIVELY CORRELATED WITH DISEASE SEVERITY. AP PATIENTS' SERUM USP25 LEVELS AFTER TREATMENT WERE SIGNIFICANTLY LOWER THAN THAT AT THE ONSET OF AP. FURTHERMORE, USP25 EXPRESSION WAS UPREGULATED IN CERULEIN-INDUCED AP IN MICE, WHILE USP25 DEFICIENCY ATTENUATES AP AND AP-RELATED MULTIPLE ORGAN INJURY. IN VIVO AND IN VITRO STUDIES SHOWED THAT USP25 EXACERBATES AP BY PROMOTING THE RELEASE OF PRO-INFLAMMATORY FACTORS AND DESTROYING TIGHT JUNCTIONS OF THE PANCREAS. WE SHOWED THAT USP25 AGGRAVATES AP AND AP-RELATED MULTIPLE ORGAN INJURY BY ACTIVATING THE SIGNAL TRANSDETER AND ACTIVATOR OF TRANSCRIPTION 3 (STAT3) PATHWAY. TARGETING THE ACTION OF USP25 MAY PRESENT A POTENTIAL THERAPEUTIC OPTION FOR TREATING AP.

Keywords: acute pancreatitis, ubiquitin-specific protease 25, multiple organ injury, tight junctions, signal transducer and activator of transcription 3 pathway

INTRODUCTION

Acute pancreatitis (AP) is characterized by autodigestion, edema, hemorrhage, and even necrosis of the pancreatic tissue after activation of pancreatin. Inflammation of the pancreas with or without organ failure can be observed during the course of pancreatitis. AP can be classified according to severity into mild acute pancreatitis (MAP), moderate severe acute pancreatitis (MSAP), and severe acute pancreatitis (SAP). Various therapeutic strategies have been developed to treat AP, but the ideal therapy remains to be determined. The research on the role of USP25 in AP is still unclear.

Ubiquitin-specific protease 25 (USP25) plays an important role in inflammation and immunity. However, the role of USP25 in acute pancreatitis (AP) is still unclear. To evaluate the role of USP25 in AP, we conducted research on clinical AP patients, USP25 wild-type (WT)/USP25 knockout (USP25−/−) mice, and pancreatic acinar cells. Our results showed that serum USP25 concentration was higher in AP patients than in healthy controls and was positively correlated with disease severity. AP patients’ serum USP25 levels after treatment were significantly lower than that at the onset of AP. Moreover, USP25 expression was upregulated in cerulein-induced AP in mice, while USP25 deficiency attenuates AP and AP-related multiple organ injury. In vivo and in vitro studies showed that USP25 exacerbates AP by promoting the release of pro-inflammatory factors and destroying tight junctions of the pancreas. We showed that USP25 aggravates AP and AP-related multiple organ injury by activating the signal transducer and activator of transcription 3 (STAT3) pathway. Targeting the action of USP25 may present a potential therapeutic option for treating AP.

Abbreviations: AMY, amylase; AP, acute pancreatitis; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CRP, C-reactive protein; Cr, creatinine; ELISA, enzyme linked immunosorbent assay kit; IHC, immunohistochemistry; IF, immunofluorescence; IL, interleukin; LIPA, lipase; MAP, mild acute pancreatitis; MSAP, moderate severe acute pancreatitis; SAP, severe acute pancreatitis; STAT3, signal transducer and activator of transcription 3; TNF, tumor necrosis factor; USP25, ubiquitin-specific protease 25.
acute pancreatitis (SAP) (Crockett et al., 2018). Approximately 20% of AP patients develop SAP, which is related to systemic inflammatory response and multiple organ injury. Lung, liver, kidney, and heart are organs that are often involved in AP-related multiple organ failure (Scherps et al., 2019). According to global estimates, the incidence of acute pancreatitis is 34 cases per 100,000 persons each year with a 95% confidence interval [23.33, 48.81], and the mortality rate is 1.60 cases per 100,000 persons each year with a 95% confidence interval [0.85, 1.58] (Xiao et al., 2016). With increase in the global obesity rate, obesity-related complications, such as cholelithiasis, hypertriglyceridemia, and diabetes, are independently related to the onset of AP (Black and Gupta, 2018). The increasing incidence of AP has brought a heavy economic burden to global medical care. However, there is still no effective method to prevent AP.

The intercellular spaces between pancreatic epithelial cells are usually closed by tight junctions. These connections are assembled from the components of adjacent cells that form a gasket-like band that surrounds the surface of each cell at the intersection of the apical and basolateral regions. This seal restricts the movement of molecules between the epithelial cavity and the interstitium according to molecule charge and size. Structurally, tight junctions are related to the actin-based cytoskeleton (Rouaud et al., 2020). Several tight junction-related proteins have been identified, and zonula occludens (ZO)-1 is the most widely used structural marker for tight junctions. It has been shown that the expression of ZO-1 is downregulated in AP and the expression of ZO-1 is negatively correlated with the degree of inflammation (Sharmila and Venkateswaran, 2017).

Deubiquitinating enzymes (DUBs) inversely regulate protein ubiquitination by dissociating ubiquitin chain molecules and maintaining the dynamic balance of cell ubiquitin. DUBs play an important role in the regulation of protein degradation and ubiquitin recovery, DNA repair pathways, and cell signal regulation (Clague et al., 2019). DUBs can be classified into six subfamilies: ubiquitin-specific proteases (USPs), ovarian tumor proteases, ubiquitin carboxy-terminal hydrolases, Josephine family, ubiquitin-interacting enzymes motif, zinc-dependent JAB1/MPN/MOV34 metalloprotease DUBs (JaMs) (Mevissen and Komander, 2017).

Ubiquitin-specific protease 25 (USP25) belongs to the cysteine protease family of DUBs, and is involved in the regulation of inflammation and immunity. Long et al. found that USP25 can promote the stability of histone acetyltransferase HBO1 in bacterial infections, thereby enhancing HBO1-mediated transcription of inflammatory genes and promoting inflammation (Long et al., 2018). USP25 is also involved in the immune regulation of colon tumors and intestinal bacterial infections by regulating the levels of Wnt and suppressor of cytokine signaling 3 (SOCS3) (Wang et al., 2020). In addition, USP25 is upregulated after viral infection and participates in the body’s antiviral response by mediating the stabilization of tumor necrosis factor (TNF) receptor associated factor 3 (TRAF3) and TRAF6 (Lin et al., 2015). However, the role of USP25 and its mechanism in acute pancreatitis remains unclear.

Here, we investigated whether USP25 affects inflammation in patients with AP. We found that serum USP25 concentrations were higher in AP patients than in healthy controls and were positively correlated with disease severity in AP patients. We demonstrated that USP25 plays a critical role in mediating AP development by activating the STAT3 pathway.

### MATERIALS AND METHODS

**Serum Collection**

Human serum samples were collected at the Renmin Hospital of Wuhan University, and informed consent was obtained from all patients and healthy controls. The study was approved by the Ethics Committee of the Renmin Hospital of Wuhan University (No. 2018 K-C089). The diagnosis of AP was based on the Atlanta classification of acute pancreatitis (2012 revision) (Banks et al., 2013). Patients’ clinical information were collected; this includes information regarding sex, age, and blood examination results, including serum amylase (AMY), lipase (LIPA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (Cr), blood urea nitrogen (BUN), and C-reactive protein (CRP). We then used the human USP25 enzyme-linked immunosorbent assay (ELISA) kit (Meilian ml-895378, Suzhou, China) to measure the patients’ serum USP25 protein levels according to the manufacturer’s instructions. Serum interleukin (IL)-6, TNF-α, and IL-1β levels were examined using ELISA kits (Quantikine, R&D Systems, United States). The clinical characteristics of the patients are summarized in Table 1. We followed up with 16 patients who were discharged from the hospital after treatment and examined the serum USP25 protein levels on admission and after treatment.

#### Induction of AP

Animal protocols were approved by the Animal Ethics Committee of Wuhan University for animal experiments (No. WDRY2018-K033). C57BL/6 USP25−/− mice were kindly provided by Dr. Chen Dong (Institute for Immunology and School of Medicine, Tsinghua University, Beijing, China), and C57BL/6 wild-type (WT) mice were purchased from the Vital River Laboratory (Beijing, China). All experimental mice were...
housed in a specific pathogen-free animal facility at the Animal Experiment Center at Renmin Hospital of Wuhan University.

A 2% agarose gel electrophoresis was used to verify the DNA of USP25WT and USP25−/− mice. C57BL/6 USP25WT and USP25−/− male mice (6–8 weeks, 20 ± 0.8 g, n = 8 per group) were randomly divided into four groups: USP25WT + normal saline (NS), USP25WT + cerulein, USP25−/− + NS, and USP25−/− + cerulein. We administered intraperitoneal injections of cerulein (Sigma-Aldrich C9026, St. Louis, MO) (50 μg/kg body weight) seven times at an interval of 1 h to induce AP in mice (Silva-Vaz et al., 2019); the control group was administered 0.9% NS. Twenty-four hours after the last injection of cerulein and NS, mouse blood was collected from the inferior vena cava after the mice were anesthetized with isoflurane. The mice were sacrificed, and the pancreas, lungs, livers, kidneys, and small intestines of mice were immediately removed.

To induce AP in vitro, rat pancreatic acinar cells (AR42J) and mouse pancreatic acinar cells (MPAC) were treated with 10−8 M cerulein, and the control group was treated with the same amount of phosphate buffered saline (PBS).

Inhibition of STAT3 Activation With Stattic

Stattic (ab120952, Abcam, Cambridge, UK) was administered to mice at a dose of 1 mg/kg/day per mouse for 7 days to inhibit STAT3 phosphorylation, and then mice were injected intraperitoneally with NS or cerulein. In the in vitro study, the cells AR42J and MPAC were incubated with 10 μM stattic for 2 h, followed by the addition of PBS or cerulein.

Activation of STAT3 Phosphorylation With Colivelin

In the colivelin treatment study, the cells AR42J and MPAC were incubated with 100 fM colivelin, followed by the addition of cerulein.

Serum Examination

The blood samples were centrifuged at 3,000 × g at 4°C for 10 min, and the serum was stored at −80°C before examination. Serum AMY, LIPA, ALT, Cr, and BUN were measured using a fully automated chemical analyzer (Chemray 800; Rayto Life Technology Co., Ltd. Shenzhen, China). Serum IL-6, TNF-α, and IL-1β levels were examined using ELISA kits (Quantikine; R&D Systems, United States) according to the manufacturer’s instructions. All samples were analyzed three times.

Histological Examination

The pancreases, lungs, livers, kidneys, and small intestines obtained from the experimental mice were fixed in 4% buffered formalin for 24 h and then embedded in paraffin. Tissue sections (4 μm) were stained with hematoxylin and eosin (H&E). The histopathological changes were analyzed under an optical microscope by two expert pathologists who were blinded to the experimental method. The pathological changes in pancreatic tissue were evaluated according to the criteria proposed by Schmidt et al., including edema, inflammation, perivascular infiltration, hemorrhage, fat necrosis, and acinar necrosis (Schmidt et al., 1992). Lung injury assessment was based on the criteria described by Osman et al., including interstitial and alveolar edema, leukocyte infiltration, and hemorrhage (Osman et al., 1998). The evaluation of liver damage was described by Moto et al., including hepatocyte necrosis, leukocyte infiltration, and vacuolation (Mota et al., 2007). The pathological changes of renal injury were evaluated according to the criteria proposed by Paller et al., examining at least 100 cortical tubules in ten different areas for renal tubular epithelial cell flattening, brush border deletion, cell membrane bubble formation, interstitial edema, cytoplasmic vacuoles, cell necrosis, and renal tubule obstruction (Paller et al., 1984). The evaluation of small intestine injury was based on the standard method proposed by Chiu et al., including the distance of the small intestine villi and the detachment of the villi from the lamina propria (Chiu et al., 1970).

Immunohistochemistry

After deparaffinization, hydration, antigen retrieval, and serum block, pancreatic sections were incubated overnight with the following primary antibodies at 4°C: CD45 (1:1,000, catalog no.21009-1-AP, Proteintech, Wuhan, China) and USP25 (1:200, catalog no. A7975, ABclonal). Goat anti-rabbit horseradish peroxidase (1:200; catalog no. AS-1107, Aspen, Wuhan, China), or goat anti-mouse horseradish peroxidase (1:200; catalog no. AS-1106, Aspen Wuhan, China) was added to the slices.

Immunofluorescence

After the paraffin sections of the pancreas were deparaffinized, washed, and blocked, ZO-1 antibody (1:1,000; catalog no. 21773-1-AP, Proteintech, Wuhan, China) was added to it and incubated at 4°C. MPAC were incubated with p-STAT3Y705 antibody (1:100; catalog no. #9145, Cell Signaling Technology) at 4°C. After washing with PBS, CY3-labeled goat anti-rabbit antibody (1:50; catalog no. AS-1109, Aspen, Wuhan, China) was added, and the nuclei were stained with 4,6-diamino-2-phenylindole (DAPI, AS1075, Aspen, Wuhan, China). To evaluate the expression level of ZO-1 and p-STAT3, ImageJ (National Institutes of Health, Bethesda, MD, USA) was used to measure the fluorescence intensity of ZO-1 and p-STAT3, and the fluorescence intensity was quantified under a high-power field.

Western Blotting

A total protein extraction kit (Beyotime Bio-technology) was used to extract total protein from different groups, and protein concentration was determined using the BCA kit (P0012, Beyotime Bio-technology, Shanghai, China). From each group, a 20 μg protein sample was electrophoresed on a 10% SDS polyacrylamide gel and then transferred to a polyvinylidene fluoride membrane. After blocking the protein with a protein-free rapid blocking buffer (catalog no. PS108P, Epizyme, Shanghai, China), polyvinylidene fluoride membranes were incubated for 12 h at 4°C with the following antibodies: USP25 antibody (1: 1,000; catalog no. A7975, ABclonal), STAT3 antibodies (1:1,000; catalog no. #9139, Cell Signaling Technology), p-STAT3 (Tyr705) antibody (1:2,000; catalog no. #9145, Cell Signaling Technology), ZO-1 antibody (1:1,000; catalog no. 21773-1-AP, Proteintech, Wuhan, China), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody (1:1,000; catalog no. #5174, Cell Signaling Technology).
Cell Culture
Mouse primary acinar cells were cultured as described below. Briefly, pancreas were isolated from 8-week-old male USP25 KO and WT C57BL/6J mice and minced for 5 min in Hank's.

Balanced salt solution (Sigma, St. Louis, MO, USA) + 10 mmol/L of HEPES (Sigma, St. Louis, MO, United States) and 0.1% bovine serum albumin (Gibco, Grand Island, NY, United States). After washing, pancreatic segments were cultured in 10 ml collagenase IA solution (Hank's balanced salt solution Contains 10 mmol/L HEPES, 0.25 mg/ml trypsin inhibitor and 200 U/ml collagenase IA [Sigma, St. Louis, MO, United States]) at 37°C for 20-30 min. Then the solution containing collagenase was removed and replaced with Dulbecco’s modified Eagle medium (Sigma, St. Louis, MO, United States) supplemented with 10% fetal bovine serum (Gibco, Grand Island, NY, United States), 1% Penicillin and streptomycin (Invitrogen, Carlsbad, CA, United States), 25 ng/ml recombinant mouse epidermal growth factor (Sigma, St. Louis, MO, United States) and 0.25 mg/ml trypsin inhibitor at 37°C, 95% humidity and 5% CO2.

AR42J cells were purchased from the American Type Culture Collection (Manassas, VA, United States). The cells were cultured in a 5% CO2 humidified incubator at 37°C in Dulbecco’s modified Eagle medium (Sigma, St. Louis, MO, United States) supplemented with 10% fetal bovine serum (Gibco, Grand Island, NY, United States), 1% Penicillin and streptomycin (Invitrogen, Carlsbad, CA, United States).

Cell Transfection
Small interfering RNA (siRNA) targeting the Usp25 gene (siRNA Usp25) and non-targeting siRNAs (NC) were purchased from GenePharma Genomics Co. Ltd. (Suzhou, China). Cells were cultured with Lipofectamine 6000 (Beyotime, China) and transfected with Usp25

Statistical Analysis
Statistical analyses were performed using the GraphPad Prism software version 8.0. Data are expressed as mean ± SD. Comparisons between the two groups were performed using the unpaired Student’s t-test for normally distributed parameters and the Wilcoxon rank-sum test for non-normally distributed parameters. The Pearson correlation analysis was used to test correlations, and one-way analysis of variance (ANOVA) combined with the Bonferroni’s post hoc test was used for multi-group testing. Statistical significance was defined at p < 0.05.

RESULTS
Serum USP25 Concentration is Higher in Patients With AP Than in Healthy Controls and Positively Correlated With the Disease Severity and Multiple Organ Injury
We collected clinical data from 79 patients diagnosed with AP (27 MAP patients, 34 MSAP patients, and 18 SAP patients) and 53 healthy controls, and serum USP25, IL-6, TNF-α, and IL-1β levels in AP patients and healthy controls were detected by ELISA. As shown in Table 1, compared with healthy individuals, the level of serum AMY, LIPA, ALT, AST, Cr, BUN, CRP, IL-6, TNF-α, and IL-1β increased significantly (p < 0.05). The levels of serum USP25 protein in patients and controls from ELISA are shown in Figure 1A. The serum USP25 levels of AP patients were significantly higher than that of the healthy controls (38.36 ± 10.27 pg/ml vs 101.97 ± 61.25 pg/ml; p < 0.05). In addition, as shown in Figure 1B, SAP patients had the highest serum USP25 protein level (161.17 ± 27.58 pg/ml), followed by MSAP patients (97.24 ± 12.31 pg/ml), and MAP patients had the lowest USP25 protein level (68.48 ± 6.82 pg/ml).

In the correlation analysis between serum markers, and USP25 (Figures 1C–IL), AMY (r = 0.3508, p < 0.05), LIPA (r = 0.6007, p < 0.05), ALT (r = 0.3399, p < 0.05), AST (r = 0.4219, p < 0.05), BUN (r = 0.5162, p < 0.05), CRP (r = 0.5453, p < 0.05), IL-6 (r = 0.4246, p < 0.05), TNF-α (r = 0.3269, p < 0.05), and IL-1β (r = 0.3501, p < 0.05) levels were positively related with the USP25 level. We followed up with 16 AP patients to compare the serum USP25 level before and after treatment (Figure 1M), and the patients’ serum USP25 levels were significantly lower after treatment than that at the onset of AP (131.19 ± 42.94 pg/ml vs 90.38 ± 26.73 pg/ml, p < 0.05).

The Expression of USP25 Is Upregulated in Cerulein-Induced AP Mice and Associated With Multiple Organ Injury
After multiple intraperitoneal injections of cerulein to induce AP in mice, mouse pancreas weight (g)/mouse weight (g) was calculated, and the mouse pancreas, lung, liver, kidney, and small intestine were examined using H&E staining. The results showed that the relative weight of the pancreas of AP mice was significantly higher than that of the control group (p < 0.05) (Supplementary Figure 2A). As shown in Figure 2A, the pancreas of AP mice showed severe edema, large acinar necrosis, inflammatory cell infiltration, and intrapancreatic hemorrhage. Histopathological examination of lung H&E of AP mice showed interstitial and intra-alveolar edema, inflammatory cell infiltration, and hemorrhage in the interstitium and alveoli. Obvious hepatocyte edema, cytoplasmic vacuolation, necrosis, loss of intercellular boundaries, and inflammatory cell infiltration were observed in the livers of AP mice. The kidneys of the AP group showed obvious pathological changes, including detachment of tubular epithelial cells, dilated renal tubules, disordered tubular structure and inflammatory cell infiltration around the renal tubules. In addition, the small intestines of the AP group showed widening of the subepithelial space at the top of the villi and peeling of the villi tip from the lamina propria or falling off in pieces. In contrast, the histology of the pancreas, lung, liver, kidney, and small intestine in the control group were normal (Figure 2A). The histological scores of different organs in the AP mice were significantly higher than those in the control group (p < 0.05) (Figure 2B).
To further verify the difference in inflammation between wild-type mice treated with saline and cerulein, we stained the tissues for a marker of inflammation (CD45) by IHC (Supplementary Figure 1A) and quantified (Supplementary Figures 1B–1F). The results showed that tissues of mice treated with cerulein had higher infiltration of inflammatory cells than that of mice treated with saline ($p < 0.05$).

The expression levels of USP25 in mouse pancreas were examined by IHC and WB. The results are shown in Figures 2C,D and Supplementary Figures 2B, 2C. The
expression levels of USP25 protein (IHC, \(p < 0.05\); WB, \(p < 0.05\)) in the pancreas of AP mice were significantly higher than those of the control group.

Examination of mouse serum AMY, LIPA, ALT, AST, Cr, and BUN levels using an automatic chemical analyzer showed that AMY (\(p < 0.05\)), LIPA (\(p < 0.05\)), ALT (\(p < 0.05\)), AST (\(p < 0.05\)), Cr (\(p < 0.05\)), and BUN (\(p < 0.05\)) of AP mice were significantly higher than those of the control group (Figure 2E). The examination of serum inflammatory factors by ELISA showed that the levels of serum IL-6 (\(p < 0.05\)), TNF-\(\alpha\) (\(p < 0.05\)), and IL-1\(\beta\) (\(p < 0.05\)) were significantly higher in AP mice than in the control group (Figure 2F).

Therefore, USP25 is upregulated in cerulein-induced AP mice and is associated with inflammation. We speculated that USP25 may promote the inflammatory response in AP.
To study the contribution of USP25 in the pathogenesis of AP, we examined cerulein-induced AP in USP25 knockout (USP25−/−) mice. The DNA identification results of the experimental mice are shown in Supplementary Figure 2D. As shown in Figure 3, compared with USP25WT mice, USP25 deficiency had a protective effect on cerulein-induced AP mice, which showed a lower degree of pancreatic inflammation and multiple organ injury. The relative weight of the pancreas of mice in the USP25−/− group was significantly lower than that of the USP25WT group (Supplementary Figure 2E). The damage to the pancreas, lung, liver, kidney, and small intestine were significantly lower in USP25−/− mice than in USP25WT mice.
and the degree of edema, necrosis, inflammatory cell infiltration, and hemorrhage of the pancreas of USP25−/− AP mice were significantly lower than those of USP25WT AP mice (p < 0.05). The lungs of USP25−/− AP mice showed less bleeding and interstitial and alveolar edema, inflammation, and cell infiltration than that of the USP25WT AP mice (p < 0.05). In
addition, hepatocellular edema, cytoplasmic vacuolation, necrosis, loss of intercellular boundaries and inflammatory cell infiltration in the livers of the USP25−/− AP mice decreased significantly (p < 0.05). Furthermore, dilated renal tubules, disordered tubular structure and inflammatory cell infiltration around the renal tubules were rarely observed in the kidneys of the USP25−/− AP mice (p < 0.05). Moreover, the villi tip and lamina propria were rarely peeled off or fell off in pieces in the small intestine of the USP25−/− AP mice (p < 0.05).

Consistent with the above mentioned histology, the levels of serum AMY (p < 0.05), LIPA (p < 0.05), ALT (p < 0.05), AST (p < 0.05), BUN (p < 0.05), and Cr (p < 0.05) of the USP25−/− AP group were significantly lower than those of the USP25WT AP group (Figures 4A–F). The results of serum IL-6, TNF-α, and IL-1β levels in mice are shown in Figures 4G–I. The levels of serum IL-6 (p < 0.05), TNF-α (p < 0.05), and IL-1β (p < 0.05) in the USP25−/− AP group were also significantly lower than those in the USP25WT AP group.

These experimental results suggest that USP25 aggravates AP and AP-related multiple organ injury.

**USP25 Aggravates AP by Destroying Tight Junctions of the Pancreas**

A study by Fallon et al. showed that in the early stage of AP, the structure and function of the paracellular barrier in the acinar and lobules are destroyed, which may be related to early clinical
features (Fallon et al., 1995). The expression of ZO-1, an important tight junction protein, decreases significantly in AP. We used IF and WB to detect the expression of tight junction proteins in mouse pancreases and the results showed that the level of ZO-1 proteins was significantly reduced (IF, p < 0.05; WB, p < 0.05) (Figures 2C,D, Supplementary Figures 2F, G). In addition, both in vivo and in vitro experiments confirmed that the damage of tight junctions in the USP25 deficiency AP group was significantly less than that in the USP25WT AP group (Figures 5A,B,D, Supplementary Figures 3D, 3H, 3I, 3N).

Therefore, USP25 Exacerbates AP by Destroying Tight Junctions of the Pancreas

To explore the possible mechanisms of USP25 in AP and AP-related multiple organ injury, we used USP25 siRNA and cerulein to intervene in AR42J. Cell protein was extracted to verify transfection efficiency (Supplementary Figures 2H, 2I), moreover, MPAC were isolated from 8-week-old male USP25 KO and WT mice, and cerulein was used to induce AP in MPAC, and then the levels of USP25, STAT3, p-STAT3 (Try705), and ZO-1 protein were examined. As shown in Figure 5A and Supplementary Figures 3A–3H, the level of p-STAT3 protein in the USP25 siRNA + cerulein group or USP25−/− + cerulein was significantly lower than that in the NC + cerulein group or USP25WT + cerulein, while the ZO-1 protein in siRNA + cerulein group or USP25−/− + cerulein was significantly higher than in NC + cerulein group or USP25WT + cerulein. Similarly, as shown in Figure 5B and Supplementary Figures 3I–3L, in cerulein-induced AP mice, the level of p-STAT3 protein in USP25−/− AP mice was significantly lower than that in USP25WT AP group, but ZO-1 in USP25−/− AP mice was significantly higher than in USP25WT AP mice. Expression levels p-STAT3 in MPAC and ZO-1 levels in pancreatic tissues respectively measured using IF were consistent with the results of the WB (Figures 5C,D and Supplementary Figures 3M–3N). These results suggest that USP25 may aggravate AP and AP-related multiple organ injury by promoting STAT3 phosphorylation.

To verify the above hypothesis, we used the STAT3 (Y705) activation inhibitor stattic to interfere with STAT3 phosphorylation in mice and the cells AR42J and MPAC. The results showed that the relative weight of the pancreas in AP group with stattic was significantly lower than that in AP group without stattic (p < 0.05) (Supplementary Figure 4A). H&E staining in various organs of mice (Figures 6, 7) showed less inflammatory damage in the AP group with stattic than in the AP group without stattic: pancreas (p < 0.05), lung (p < 0.05), liver (p < 0.05), kidney (p < 0.05), and small intestine (p < 0.05). In addition, the levels of AMY (p < 0.05) and LIPA (p < 0.05) in the AP group with stattic were significantly lower than those in the AP group without stattic (Figures 6D,E).

Furthermore, WB was used to examine the protein expression levels in the AR42J, MPAC, and mouse pancreatic tissue. The results are shown in Figures 8A,B, Supplementary Figures 4B–4M, where the levels of USP25 protein (p < 0.05), p-STAT3 (p < 0.05) of AP group with stattic were significantly reduced compared to those in AP group without stattic. In contrast, the expression of ZO-1 protein in AP group with stattic was significantly higher (p < 0.05) than in AP group without stattic. We used the IF method to examine the expression level of ZO-1 in the pancreatic tissue (p < 0.05), which was consistent with the results of WB (Figure 8C and Supplementary Figure 4N).

Consistent with the above mentioned results, ELISA results of serum inflammatory factors showed that compared with the AP group without stattic, the serum IL-6 (p < 0.05), TNF-α (p < 0.05), and IL-1β (p < 0.05) in the AP group with stattic were significantly reduced, suggesting that inflammation of pancreas in AP group was reduced (Supplementary Figures 5A–5C).

To further verify that USP25 regulates STAT3, the STAT3 agonist colivelin was added to AR42J and MPAC, and then cerulein was used to induce AP in the cells. As shown in Figure 8D and Supplementary Figures 5D–5K, after the addition of colivelin to cells, the expression of p-STAT3 (Y705) increased (p < 0.05), while the expression of ZO-1 decreased significantly (p < 0.05), which suggest that activation of STAT3 by colivelin counteracted the protective effect of USP25 deficiency on AP in AR42J and MPAC. Therefore, USP25 aggravates AP and AP-related multiple organ injury by destroying tight junctions through activating the STAT3 pathway.

DISCUSSION

Patients with AP can experience systemic damage caused by a systemic inflammatory response, which manifests as multiple organ injuries. The proportion of AP patients with organ failure is 8–20% (Hamada et al., 2014). In tertiary health care hospitals with many AP patients, the proportion of SAP patients may be as high as 40% (Schepers et al., 2019). The inflammatory response often involves the lungs, heart, liver, and kidney, which seriously affects the prognosis of patients. In our study, 22.78% of patients were diagnosed with SAP, the proportion of patients with SAP was consistent with previous studies.

Inflammation is a local and systemic pathological reaction in AP. During the development of AP, pancreatic acinar cells release digestive enzymes, inflammatory cytokines, and pro-inflammatory mediators into the blood circulation, including IL-6, TNF-α, and IL-1β (Habtezion et al., 2019). Pro-inflammatory mediators enter the liver through the portal vein, leading to the activation and proliferation of intrinsic Kupffer cells, which in turn produce more pro-inflammatory cytokines, inducing early liver injury and the release of hepatocyte pro-inflammatory factors (Wang et al., 2017). Liver-derived cytokines activate alveolar macrophages through the intravenous route to release chemotactic cytokines to recruit neutrophils. Neutrophils and elevated circulating pro-
FIGURE 6 | USP25 aggravates acute pancreatitis and acute pancreatitis-related lung injury by activating STAT3 pathway in vivo. STAT3 (Y705) activation inhibitor-Stat3 was used to interfere with STAT3 phosphorylation in USP25WT and USP25−/− mice (n = 8 per group), then cerulein was used to induce AP in mice. (A) H&E staining of pancreas, lung in eight experimental groups. (B–C) The histological scores of pancreas, lung in eight experimental groups. (D–E) Mice serum AMY, LIPA were examined by automatic chemical analyzer in eight experimental groups. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001.
inflammatory cytokines severely damage the alveolar epithelium, leading to pulmonary edema, and then produce inflammatory cytokines that cause systemic inflammatory response syndrome (Yang et al., 2016). Inappropriate inflammatory signal activation and systemic inflammatory response syndrome are powerful triggers for local kidney inflammation and subsequent tissue damage (Lee et al., 2019).

In this study, it was observed that serum AMY, LIPA, etc., and pro-inflammatory cytokines (IL-6, TNF-α, IL-1β) increased after cerulein injection, and the pathological damage to the pancreas and other organs (including liver, lung, kidney, and small intestine) were aggravated. These results were consistent with the results of previous studies (Wen et al., 2020), indicating that cerulein injection can successfully induce AP in mice.

Our results show that serum USP25 is highly expressed in patients with AP and is positively correlated with inflammation and organ injury. In the cerulein-induced AP mice study, it was further confirmed that the expression of USP25 was upregulated...
This conclusion is consistent with the following previous studies that have shown that USP25 plays an important role in immune regulation. Lipopolysaccharides and viral infections activate USP25 transcription through signals triggered by type I interferon (IFN). In addition, signals triggered by type I IFN transduction induce the expression and protein synthesis of IFN regulatory factor 7 (IRF7). IRF7 binds to the USP25 promoter to activate the transcription of the Usp25 gene (Ren et al., 2016). USP25 can promote the intestinal inflammatory response during bacterial infection, and the goblet cells and Paneth cells in USP25 WT mice are significantly decreased compared with those in the USP25−/− mice (Wang et al., 2020).

STAT3 activation plays an important role in the development of AP. Research by Li et al. found that when mouse AP was caused by intraductal hypertension, STAT3 phosphorylation was activated, serum AMY, IL-6, TNF-α, and IL-1β levels were all significantly increased, and the tight junction of the pancreas disappeared (the expression levels of ZO-1 and occludin decreased) (Wen et al., 2018). In addition, studies have shown that activation of STAT3 aggravates AP-related liver damage in cerulein-induced AP in mice (Ren et al., 2021), which is
consistent with our study result that STAT3 activation in pancreatitis leads to damage to tight junctions.

USP25, as a member of the deubiquitination family, can effectively reduce protein degradation by the proteasome through reversibly removing the ubiquitin chain. USP25 may regulate the inflammatory response in AP through multiple signaling pathways. Nino et al. found that USP25 restrained the degradation of the EGFR by assisting in the association of the E3 ubiquitin ligase c-Cbl with EGFR, thereby modulating the amplitude of ubiquitylation on the receptor. (Nino et al., 2020). Previously, Ardito et al. demonstrated that EGFR was required for cerulein-induced pancreatitis and kras-induced tumorigenesis (Ardito et al., 2012). Moreover, Zhong et al. identified USP25 as a regulator of TLR signaling, USP25 was recruited to the TLR4 signaling complex, and specifically reversed the Lys48-linked ubiquitination of TRAF3 that was mediated by the E3 ubiquitin ligase cIAP2 (cellular inhibitor of apoptosis 2) (Zhong et al., 2013). Previously, Sharif et al. demonstrated that TLR4 played a significant pro-inflammatory role in the progression of acute pancreatitis (Sharif et al., 2009). Furthermore, when mouse colitis is associated with bacterial infection, USP25 can aggravate colitis by promoting STAT3 phosphorylation (Wang et al., 2020), consistent with previous studies, our study found that USP25 aggravates AP by regulating STAT3 (especially p-STAT3). We speculate that USP25 regulates AP by removing the ubiquitin chain of p-STAT3 to reduce ubiquitination and degradation of p-STAT3. The increase of p-STAT3 activates the inflammatory signaling pathway, thereby increasing the release of inflammatory factors, which damages tight junctions and aggravates acute pancreatitis. However, this speculation needs to be further confirmed by experiments.

CONCLUSION

Our current work demonstrates the role of USP25 in AP and AP-related multiple organ injuries. First, USP25 is highly expressed in patients with AP and is positively correlated with the degree of inflammation in AP and AP-related multiple organ injury. Second, we confirmed that USP25 deficiency can alleviate cerulein-induced AP and AP-related multiple organ injury. Last, our results show that USP25 promotes the release of pro-inflammatory factors and destroys the tight junction of the pancreas by activating the STAT3 pathway, thereby aggravating AP. Therefore, our conclusion emphasizes the role of USP25 in exacerbating AP and AP-related multiple organ injuries. Targeting the action of USP25 may be a potential therapeutic option for treating AP.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Animal Ethics Committee of Wuhan University. The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by Animal Ethics Committee of Wuhan University.

AUTHOR CONTRIBUTIONS

Authors’ contributions ZL made a significant contribution to study design, execution and write this paper. MQ, ST, QY, JL, SW, MJ, RY, SZ, JL, and YW made a significant contribution to acquisition of data, analysis and interpretation. WD drafted, revised the article and agreed to take responsibility and be accountable for the contents of the article.

FUNDING

National Natural Science Foundation of China, Grant/Award Number: 81870392.

ACKNOWLEDGMENTS

We are grateful to healthy controls and acute pancreatitis patients who provided serum samples and appreciate Chen Dong who kindly provided USP25 knockout mice for us.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2021.806850/full#supplementary-material

Supplementary Figure S1 | Cerulein induces acute pancreatitis and acute pancreatitis-related multiple organ injury in mice. Wide type mice were randomly divided into 2 groups, control group: USP25WT+ normal saline (NS), AP group: USP25WT+ cerulein. (A) Tissues of pancreas, lung, liver, kidney, and small intestine from two groups were stained for CD45. (B−F) The number of CD45 positive cells in organs from mice treated with saline or cerulein were quantified.

Supplementary Figure S2 | The expression of USP25 is up-regulated in cerulein-induced acute pancreatitis mice and USP25 deficiency attenuates pancreatic inflammation. Wide type mice (WT) were randomly divided into 2 groups, control group: USP25WT+ normal saline (NS), AP group: USP25WT+ cerulein. Besides, USP25 knock-out mice were also randomly divided into 2 groups, control group: USP25−/− normal saline (NS), AP group: USP25−/− cerulein. (A) The relative weight (the mouse pancreas weight (g)/mouse weight (g)) of the pancreas from four mice groups (USP25WT+ NS, USP25WT+cerulein, USP25−/−NS, USP25−/− cerulein) were compared. (B) The protein expression of ZO-1 measured by Western blotting in two WT groups. (C) The protein expression of USP25 measured by Western blotting in two WT groups examined by immunohistochemistry were quantified. (D) The expression level of USP25 protein in two WT groups examined by immunoblotting were quantified. (E) The protein expression of USP25 measured by Western blotting in two WT groups examined by immunohistochemistry were quantified. (F) The expression level of ZO-1 measured by immunofluorescence were quantified in two WT groups. (G) The protein expression of ZO-1 measured by Western blotting were quantified.
Western blotting in two WT groups were quantified. (H, I) The protein expression of USP25 in AR42J cells cocultured with PBS (Control), nontargeting SiRNA (NC), S001, S002 or S003 were examined by Western blotting and quantified respectively. *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001.

Supplementary Figure S3 | USP25 deficiency attenuates pancreatic inflammation and acute pancreatitis-related multiple organ injury in vivo (A-L). The protein expression of USP25, STAT3, p-STAT3Y705 and ZO-1 in AR42J, MPAC (NC+PBS, NC+cerulein, USP25 SRNA+PBS, USP25 SRNA+ cerulein) and mice (USP25WT+ NS, USP25WT+cerulein, USP25−/−NS, USP25−/−+ cerulein) in four groups measured by Western blotting were quantified. (M) The protein expression of p-STAT3Y705 measured by and immunofluorescence were quantified in MPAC cells of two groups: USP25WT−/−+ cerulein, USP25−/−+ cerulein. (N) The protein expression of ZO-1 measured by immunofluorescence were quantified in four mice groups: USP25WT+ NS, USP25WT+cerulein, USP25−/−NS, USP25−/−+ cerulein. The expression level of ZO-1 protein in two groups examined by immunofluorescence were quantified. *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001.

Supplementary Figure S4 | USP25 aggravates acute pancreatitis and acute pancreatitis-related multiple organ injury by destroying tight junctions through activating STAT3 pathway. Static was used to interfere with STAT3 phosphorylation in AR42J cells (nontargeting SiRNA(NC) and USP25 SRNA (USP25WT−/−)) and mice (USP25WT−/−+ mice), then cerulein was used to induce AP. (A) The relative weight (the mouse pancreas weight (g)/mouse weight (g) of the pancreas in eight groups were compared. (B-M) The protein expression of USP25, STAT3, p-STAT3Y705 and ZO-1 measured by Western blotting in AR42J, MPAC cells and tissues from mice of eight groups were quantified. (N) The expression levels of ZO-1 protein in eight groups examined by immunofluorescence were quantified. *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001.

REFERENCES

Ardito, C. M., Grüner, B. M., Takeuchi, K. K., Lubeseder-Martellato, C., Teichmann, N., Mazur, P. K., et al. (2012). EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis. Cancer Cell 22, 304–317. doi:10.1016/j.ccr.2012.07.024

Banks, P. A., Bollen, T. L., Dervenis, C., Gooszen, H. G., Johnson, C. D., Sarr, M. G., Banks, D. D., and Gupta, S. K. (2018). Gastrointestinal Complications and Management of Obesity. Gastroenterology 154, 1655–1658. doi:10.1053/j.gastro.2018.08.012

Black, D. D., and Gupta, S. K. (2018). Gastrointestinal Complications and Management of Obesity. Gastroenterology 154, 1655–1658. doi:10.1053/j.gastro.2018.08.012

Chiu, C.-J., Mcardle, A. H., Brown, R., Scott, H. J., and Gurd, F. N. (1970). Intestinal Mucosal Lesion in Low-Flow States. Arch. Surg. 101, 478–483. doi:10.1001/archsurg.1970.01340280030009

Clague, M. J., Urbé, S., and Komander, D. (2019). Breaking the Chains: Deubiquitylating Enzyme Specificity Begets Function. Nat. Rev. Mol. Cell Biol 20, 338–352. doi:10.1038/s41580-019-0099-1

Crockett, S., Falck-Ytter, Y., Wani, S., and Gardner, T. B. (2018). Acute Pancreatitis Guideline. Gastroenterology 154, 1102. doi:10.1053/j.gastro.2018.02.029

Fallon, M. B., Gorelick, F. E., Anderson, J. M., Mennone, A., Saluja, A., and Steer, M. L. (1995). Effect of Cerulein Hyperstimulation on the Paracellular Barrier of Rat Exocrine Pancreas. Gastroenterology 108, 1863–1872. doi:10.1016/S0016-5085(95)00151-5

Habtezion, A., Gukovska, A. S., and Pandol, S. J. (2019). Acute Pancreatitis: A Multifaceted Set of Organelle and Cellular Interactions. Gastroenterology 156, 1941–1950. doi:10.1053/j.gastro.2018.11.082

Hamada, S., Masamune, A., Kikuta, K., Hirota, M., Tsuji, I., Shimosegawa, T., et al. (2014). Nationwide Epidemiological Survey of Acute Pancreatitis in Japan. Pancreas 43, 1244–1248. doi:10.1097/MPA.0000000000000200

Lee, K.-H., Tseng, W.-C., Yang, C.-Y., and Tarrng, D.-C. (2019). The Anti-inflammatory, Anti-oxidative, and Anti-apoptotic Benefits of Stem Cells in Acute Ischemic Kidney Injury. Ijms 20, 3529. doi:10.3390/ijms20143529.35290.ijms20143529

Lin, D., Zhang, M., Zhang, M.-X., Ren, Y., Jin, J., Zhao, Q., et al. (2015). Induction of USP25 by Viral Infection Promotes Innate Antiviral Responses by Mediating the Stabilization of TRAF3 and TRAF6. Proc. Natl. Acad. Sci. USA 112, 11324–11329. doi:10.1073/pnas.1509968112

Long, C., Lai, Y., Li, J., Huang, J., and Zou, C. (2018). IPS Promotes HB01 Stability via USP25 in Modulate Inflammatory Gene Transcription in THP-1 Cells. Biochim. Biophys. Acta (Bba) - Gene Regul. Mech. 1861, 773–782. doi:10.1016/j.bbagrm.2018.08.001

Mevisser, T. E. T., and Komander, D. (2017). Mechanisms of Deubiquitination Specificity and Regulation. Annu. Rev. Biochem. 86, 159–192. doi:10.1146/annurev-biochem-061516-044916

Mota, R., Sánchez-Bueno, F., Berenguer-Pina, J. J., Hernández-Espinosa, D., Parrilla, P., and Yélamos, J. (2007). Therapeutic Treatment with poly(ADP-Ribose) Polymerase Inhibitors Attenuates the Severity of Acute Pancreatitis and Associated Liver and Lung Injury. Br. J. Pharmacol. 151, 998–1005. doi:10.1038/sj.bjp.0707310

Niño, C. A., Wollscheid, N., Giangreco, G., Masiero, E., and Polo, S. (2020). USP25 Regulates ERG Factor by Modulating EGF-Induced Ubiquitination Dynamics. Biomolecules 10, 1548. doi:10.3390/biom1011548

Osman, M. O., Kristensen, J. U., Jacobsen, N. O., Lausten, S. B., Deleuran, B., Deleuran, M., et al. (1998). A Monoclonal Anti-interleukin 8 Antibody (WS-4) Inhibits Cytokine Response and Acute Lung Injury in Experimental Severe Acute Necrotising Pancreatitis in Rats. Gut 43, 232–239. doi:10.1136/gut.43.2.232

Paller, M. S., Hoidal, J. R., and Ferris, T. F. (1984). Oxygen Free Radicals in Ischemic Acute Renal Failure in the Rat. J. Clin. Invest. 74, 1156–1164. doi:10.1172/JCI111524

Ren, Y., Liu, W., Zhang, L., Zhang, J., Bi, J., Wang, T., et al. (2021). Milk Fat Globule EGF Factor 8 Supports Mitochondrial Function via Intrinmedic-mediated Activation of the FAK-STAT3 Signaling Pathway in Acute Pancreatitis. Clin. Translational Med. 11, e295. doi:10.1002/ctm2.295

Ren, Y., Zhao, Y., Lin, D., Xu, X., Zhu, Q., Yao, J., et al. (2016). The Type I Interferon-IRF7 Axis Mediates Transcriptional Expression of Usp25 Gene. J. Biol. Chem. 291, 13206–13215. doi:10.1074/jbc.M116.718080

Rouaud, F., Sluymsmans, S., Illinois, A., Shah, J., Vasileva, E., and Citi, S. (2020). Scaffolding Proteins of Vertebrate Apical Junctions: Structure, Functions and Biophysics. Biochim. Biophys. Acta (Bba) - Membranes 1862, 183399. doi:10.1016/j.bbamem.2020.183399

Scarpelli, G. R., and Venkateswaran, G. (2017). Protective Effect of Bacillus subtilis CCR5 from Bacillus Subtilis CCR5 on Cerulein-Induced Pancreatitis. Biochem. Biophysical Res. Commun. 491, 455–462. doi:10.1016/j.bbrc.2017.07.054
Silva-Vaz, P., Abrantes, A. M., Castelo-Branco, M., Gouveia, A., Botelho, M. F., and Tralhão, J. G. (2019). Murine Models of Acute Pancreatitis: A Critical Appraisal of Clinical Relevance. *Ijms* 20, 2794. doi:10.3390/ijms20112794

Wang, J.-L., Chen, Y., Song, X.-Q., Lu, M.-L., Zhao, B., Ma, L., et al. (2017). Biliary Tract External Drainage Protects against Multiple Organs Injuries of Severe Acute Pancreatitis Rats via Heme Oxygenase-1 Upregulation. *Pancreatology* 17, 219–227. doi:10.1016/j.pan.2017.01.012

Wang, X.-M., Yang, C., Zhao, Y., Xu, Z.-G., Yang, W., Wang, P., et al. (2020). The Deubiquitinase USP25 Supports Colonic Inflammation and Bacterial Infection and Promotes Colorectal Cancer. *Nat. Cancer* 1, 811–825. doi:10.1038/s43018-020-0089-4

Wen, L., Javed, T. A., Dobbs, A. K., Brown, R., Niu, M., Li, L., et al. (2020). The Protective Effects of Calcineurin on Pancreatitis in Mice Depend on the Cellular Source. *Gastroenterology* 159, 1036–1050. doi:10.1053/j.gastro.2020.05.051

Wen, L., Javed, T. A., Yimlamai, D., Mukherjee, A., Xiao, X., and Husain, S. Z. (2018). Transient High Pressure in Pancreatic Ducts Promotes Inflammation and Alters Tight Junctions via Calcineurin Signaling in Mice. *Gastroenterology* 155, 1250–1263. doi:10.1053/j.gastro.2018.06.036

Xiao, A. Y., Tan, M. L. Y., Wu, L. M., Asrani, V. M., Windsor, J. A., Yadav, D., et al. (2016). Global Incidence and Mortality of Pancreatic Diseases: a Systematic Review, Meta-Analysis, and Meta-Regression of Population-Based Cohort Studies. *Lancet Gastroenterol. Hepatol.* 1, 45–55. doi:10.1016/S2468-1253(16)30004-8

Yang, R., Zhu, S., and Tonnessen, T. I. (2016). Ethyl Pyruvate Is a Novel Anti-inflammatory Agent to Treat Multiple Inflammatory Organ Injuries. *J. Inflamm.* 13, 37. doi:10.1186/s12950-016-0144-1

Zhong, B., Liu, X., Wang, X., Liu, X., Li, H., Darnay, B. G., et al. (2013). Ubiquitin-specific Protease 25 Regulates TLR4-dependent Innate Immune Responses through Deubiquitination of the Adaptor Protein TRAF3. *Sci. Signal.* 6, ra35. doi:10.1126/scisignal.2003708

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Liu, Qi, Tian, Yang, Liu, Wang, Ji, Yu, Zeng, Li, Wei and Dong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.